+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
ID05841615

Safety and Effectiveness of Combining Pulmonary Vein Isolation with Renal Denervation in Treating Atrial Fibrillation and High Blood Pressure

Led by The First Affiliated Hospital of Xiamen University · Updated on 2024-03-13

120

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the effects and safety of combining Pulmonary Vein Isolation PVI and Renal Denervation RDN in people with Atrial Fibrillation AF and Hypertension HTN. This study addresses the link between increased sympathetic tension, AF, and HTN, and the high failure rate of PVI alone in treating AF. The goal is to see if adding RDN to PVI offers better outcomes for patients. Participants will receive one of two treatments PVI alone or PVI combined with RDN. The PVI procedure isolates pulmonary veins to stop abnormal signals causing AF, guided by the CARTO mapping system. The RDN procedure involves radiofrequency ablation targeting the renal artery nerves on both sides to reduce sympathetic nerve activity. Each side has 13 ablation targets, with energy applied for 40 seconds per target. Throughout the study, researchers will monitor participants for up to two years after the procedures for major and complex adverse events. They will assess safety and effectiveness by tracking specific malignant and complex endpoint events during this period. Participants will be followed closely to evaluate treatment outcomes and any complications related to the procedures.

CONDITIONS

Brief Title

Pulmonary Vein Isolation (PVI) Combined With Renal Denervation (RDN) in Atrial Fibrillation (AF) and Hypertension (HTN)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here